JP2018087760A - Pretreatment method for imaging mass analysis - Google Patents
Pretreatment method for imaging mass analysis Download PDFInfo
- Publication number
- JP2018087760A JP2018087760A JP2016231372A JP2016231372A JP2018087760A JP 2018087760 A JP2018087760 A JP 2018087760A JP 2016231372 A JP2016231372 A JP 2016231372A JP 2016231372 A JP2016231372 A JP 2016231372A JP 2018087760 A JP2018087760 A JP 2018087760A
- Authority
- JP
- Japan
- Prior art keywords
- sample
- acid
- imaging mass
- pretreatment method
- mass spectrometry
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
Description
本発明は、イメージング質量分析の前処理方法に関する。 The present invention relates to a preprocessing method for imaging mass spectrometry.
イメージング質量分析は、生体組織切片等の試料の2次元領域内の複数の測定点に対しそれぞれ質量分析を行うことにより、特定の質量を有する物質の分布を調べる手法である。イメージング質量分析装置は、試料導入部、イオン源、分離分析部、及び、データ処理部からなる(特許文献1,2)。 Imaging mass spectrometry is a technique for examining the distribution of substances having a specific mass by performing mass analysis on each of a plurality of measurement points in a two-dimensional region of a sample such as a biological tissue section. The imaging mass spectrometer includes a sample introduction unit, an ion source, a separation analysis unit, and a data processing unit (Patent Documents 1 and 2).
イメージング質量分析では脂質等の低分子を対象とするのが主であるが、超高齢化社会を迎えた我が国において、アルツハイマー病発症メカニズム解明のための脳病理研究にイメージング質量分析が適用されることが期待される。また、広く神経疾患一般、さらには生体組織全般への本技術の応用は、従来の病理学研究との相乗効果が期待される。 Imaging mass spectrometry is mainly aimed at small molecules such as lipids, but imaging mass spectrometry is applied to brain pathological research to elucidate the mechanism of the onset of Alzheimer's disease in Japan, which has reached a super-aging society. There is expected. In addition, the application of this technology to general neurological diseases in general and to biological tissues in general is expected to have a synergistic effect with conventional pathological research.
しかしながらペプチドやタンパク質等の生物試料のイメージング質量分析では、測定対象が比較的大きな分子であるためイオン化が困難である。 However, in imaging mass spectrometry of biological samples such as peptides and proteins, ionization is difficult because the measurement target is a relatively large molecule.
本発明はかかる問題点に鑑みてなされたものであって、生物試料等のイオン化が困難な試料であっても、適切なイメージング質量分析を可能とするイメージング質量分析の前処理方法を提供することを目的とする。 The present invention has been made in view of such problems, and provides a preprocessing method for imaging mass spectrometry that enables appropriate imaging mass spectrometry even for samples that are difficult to ionize, such as biological samples. With the goal.
本発明にかかるイメージング質量分析の前処理方法は、試料台に載置された試料を酸蒸気にて処理することを特徴とする。 The pretreatment method of imaging mass spectrometry according to the present invention is characterized in that a sample placed on a sample stage is treated with acid vapor.
本発明によれば、生物試料等のイオン化が困難な分子であっても、適切なイメージング質量分析が可能となる。 According to the present invention, appropriate imaging mass spectrometry is possible even for molecules that are difficult to ionize, such as biological samples.
以下、添付の図面を参照して本発明の実施形態について具体的に説明するが、当該実施形態は本発明の原理の理解を容易にするためのものであり、本発明の範囲は、下記の実施形態に限られるものではなく、当業者が以下の実施形態の構成を適宜置換した他の実施形態も、本発明の範囲に含まれる。 Hereinafter, embodiments of the present invention will be specifically described with reference to the accompanying drawings. However, the embodiments are for facilitating understanding of the principle of the present invention, and the scope of the present invention is as follows. The present invention is not limited to the embodiments, and other embodiments in which those skilled in the art appropriately replace the configurations of the following embodiments are also included in the scope of the present invention.
図1に示されるように、イメージング質量分析装置900は、試料導入部100と、例えばMALDI(Matrix Assisted Laser Desorption Ionization)であるイオン源200と、例えば飛行時間型質量分析計TOF-MS(Time-of-Flight Mass Spectrometry)である分離分析部300と、データ処理部400と、からなる。試料導入部100で試料が装置に導入され、イオン源200で試料がイオン化され、分離分析部300でイオンが質量の違いによって分離されて検出され、データ処理部400でデータ処理される。 As shown in FIG. 1, an imaging mass spectrometer 900 includes a sample introduction unit 100, an ion source 200 such as MALDI (Matrix Assisted Laser Desorption Ionization), and a time-of-flight mass spectrometer TOF-MS (Time-MS). A separation analysis unit 300 that is of-flight mass spectrometry) and a data processing unit 400 are included. A sample is introduced into the apparatus by the sample introduction unit 100, the sample is ionized by the ion source 200, ions are separated and detected by the difference in mass by the separation analysis unit 300, and data processing is performed by the data processing unit 400.
(1)前処理工程
試料は、イオン化しにくい性質を有する難イオン化性の試料であり、例えば生体組織切片である。生体組織切片は、タンパク質凝集体を含有する組織切片である。凝集体を形成するタンパク質は、例えばアミロイドβ、タウ、αシヌクレイン、ハンチントン、TDP-43(TAR DNA-binding protein 43 kDa)である。
(1) Pretreatment step The sample is a non-ionizable sample having a property of being difficult to ionize, for example, a biological tissue section. A biological tissue section is a tissue section containing protein aggregates. The protein forming the aggregate is, for example, amyloid β, tau, α-synuclein, Huntington, TDP-43 (TAR DNA-binding protein 43 kDa).
生体組織切片は、顕微鏡用の切片作成方法と同等に作成されるが、凍結組織切片作成時に使用されているOCT(Optimal Cutting Temperature)コンパウンドの成分には合成高分子が含まれておりイオン化の妨げになるため、コンパウンドによる包埋を行わずに組織切片を作成する。作成した組織切片は、組織中の脂質がイオン化を妨げるのでエタノール水にて脂質が洗い流され、カルノア液(無水エタノール:クロロホルム:(氷)酢酸=6:3:1)にて組織固定され、真空乾燥された後に試料台に載置される。 Biological tissue sections are prepared in the same way as the section preparation method for microscopes, but the components of OCT (Optimal Cutting Temperature) compound used when preparing frozen tissue sections contain a synthetic polymer, which prevents ionization. Therefore, a tissue section is prepared without embedding with a compound. The prepared tissue slices prevent the ionization of lipids in the tissue, so that the lipids are washed away with ethanol water, fixed in tissue with Carnoy's solution (anhydrous ethanol: chloroform: (ice) acetic acid = 6: 3: 1), and vacuumed. After being dried, it is placed on the sample stage.
試料台は例えばスライドガラスである。イオン源200で生成したイオンを電圧の勾配によって分離分析部300に導入するため、試料が保持されているスライドガラスには電圧をかけることになり、スライドガラスはITOコーティングスライドガラスであることが好ましい。 The sample stage is, for example, a slide glass. Since ions generated by the ion source 200 are introduced into the separation / analysis unit 300 by a voltage gradient, a voltage is applied to the slide glass holding the sample, and the slide glass is preferably an ITO-coated slide glass. .
本実施形態にかかる発明では、試料導入部100により測定試料となる試料が装置に導入される前に、試料のイオン化の前処理として、試料台に載置された試料が酸蒸気にて処理される。 In the invention according to this embodiment, the sample placed on the sample stage is treated with acid vapor as a pretreatment for ionization of the sample before the sample to be measured is introduced into the apparatus by the sample introduction unit 100. The
酸蒸気処理は、試料台に載置された試料を密閉容器内に設置し、熱により揮散したガス状の酸を該密閉容器内に充満させ、試料をガス状の酸に曝す処理である。必ずしもこのような理論に拘泥されるわけではないが、酸蒸気処理によるガス状の酸が試料のpHを下げて塩基性度を高めることによりイオン化が促進される。 The acid vapor treatment is a treatment in which a sample placed on a sample stage is placed in a sealed container, a gaseous acid volatilized by heat is filled in the sealed container, and the sample is exposed to a gaseous acid. Although not necessarily bound by such theory, ionization is promoted by reducing the pH of the sample and increasing the basicity of the gaseous acid by the acid vapor treatment.
酸蒸気処理に使用される酸は、試料のイオン化を促進できるものであれば特に限定されるものではなく、例えば、ギ酸、硫酸、酢酸、クエン酸等であるが、好ましくはギ酸である。酸蒸気処理の温度は、揮散したガス状の酸を密閉容器内に充満させることができるものであれば特に限定されるものではないが、例えば50℃〜90℃、好ましくは60℃〜80℃にて行うことが可能である。酸蒸気処理の温度は、例えば1分〜30分であり、好ましくは5分〜10分である。 The acid used for the acid vapor treatment is not particularly limited as long as it can accelerate the ionization of the sample. For example, formic acid, sulfuric acid, acetic acid, citric acid and the like are preferable, but formic acid is preferable. The temperature of the acid vapor treatment is not particularly limited as long as the vaporized gaseous acid can be filled in the sealed container, but for example, 50 ° C to 90 ° C, preferably 60 ° C to 80 ° C. It is possible to do in. The temperature of the acid vapor treatment is, for example, 1 minute to 30 minutes, preferably 5 minutes to 10 minutes.
(2)試料導入工程
次に酸蒸気処理された試料に、例えばエアブラシにより均一な薄膜状のマトリックスが塗布され、乾燥により結晶化される。マトリックスはレーザーエネルギー伝達の仲介を可能とするものであれば特に限定されるものではないが、例えばシナピン酸(3,5-ジメトキシ-4-ヒドロキシケイ皮酸)、CHCA(α-シアノ-4-ヒドロキシケイ皮酸)、フェルラ酸(trans-4-ヒドロキシ-3-メトキシケイ皮酸)、ゲンチジン酸(2,5-ジヒドロキシ安息香酸)、HPA(3-ヒドロキシピコリン酸)、ジスラノール(1,8-ジヒドロキシ-9,10-ジヒドロアントラセン-9-オン)等を使用することができ、好ましくはシナピン酸である。
(2) Sample introduction step Next, a uniform thin-film matrix is applied to the acid vapor-treated sample by, for example, an airbrush, and crystallized by drying. The matrix is not particularly limited as long as it can mediate laser energy transfer. For example, sinapinic acid (3,5-dimethoxy-4-hydroxycinnamic acid), CHCA (α-cyano-4-hydroxy) Hydroxycinnamic acid), ferulic acid (trans-4-hydroxy-3-methoxycinnamic acid), gentisic acid (2,5-dihydroxybenzoic acid), HPA (3-hydroxypicolinic acid), disranol (1,8- Dihydroxy-9,10-dihydroanthracen-9-one) can be used, and sinapinic acid is preferred.
試料導入部100は、例えばITOコーティングスライドガラスと、スライドガラスを支持する支持台であるスライドガラスアダプタとからなり、この試料導入部100により試料が装置に導入される。 The sample introduction unit 100 includes, for example, an ITO-coated slide glass and a slide glass adapter that is a support for supporting the slide glass. The sample introduction unit 100 introduces a sample into the apparatus.
(3)イオン化工程
イオン源200は試料の物性により適宜選択可能であるが、例えばMALDIである。MALDIは、タンパク質等の生体高分子解析に好適なイオン化方法である。MALDIのイオン化法は、おもにマトリックス由来のH+(プロトン)が試料に付加した擬分子イオンを生成するため、非常にソフトなイオン化であり、また多価イオンを生成しにくいので解釈の容易なスペクトルを得ることが可能である。また難溶解性の試料でも固相のままマトリックスと混合することによってイオン化させることが可能である。イオン化源のレーザは、例えば窒素レーザやYAGレーザ等である。
(3) Ionization step The ion source 200 can be appropriately selected depending on the physical properties of the sample, and is, for example, MALDI. MALDI is an ionization method suitable for analysis of biopolymers such as proteins. The MALDI ionization method is a very soft ionization because the matrix-derived H + (protons) generate pseudo-molecular ions added to the sample, and the spectrum is easy to interpret because it is difficult to generate multivalent ions. It is possible to obtain Moreover, even a hardly soluble sample can be ionized by mixing with a matrix in a solid phase. The laser of the ionization source is, for example, a nitrogen laser or a YAG laser.
なお、イオン源はMALDIに限定されるものではなく、例えばESI、EI、FAB等でも可能である。 The ion source is not limited to MALDI, and for example, ESI, EI, FAB or the like is also possible.
(4)分離分析工程
飛行時間型質量分析計TOF-MSでは、レーザによりイオン化された物質は、一定の電場によりエネルギーを受け、飛行を始める。ドリフト領域では、質量の小さいものはスピードが速く、大きいものはスピードが遅いことから、検出器への到達時間に差が生じ、その時間差を計測しそれを質量に変換することにより質量スペクトルが得られる。
(4) Separation and analysis process In the time-of-flight mass spectrometer TOF-MS, the material ionized by the laser receives energy from a certain electric field and begins to fly. In the drift region, a small mass has a high speed and a large mass has a slow speed.Therefore, a difference occurs in the arrival time at the detector, and the mass spectrum is obtained by measuring the time difference and converting it to a mass. It is done.
なお、分離分析部はTOFに限定されるものではなく、例えばIT、Sector、Q-pole等でも可能である。 The separation / analysis unit is not limited to the TOF, and may be, for example, IT, Sector, Q-pole, or the like.
(5)データ処理工程
イメージング専用のソフトウエアにより、取得した質量スペクトルを下にデータ解析が行われ、画像として可視化される。
(5) Data processing step Data analysis is performed on the acquired mass spectrum with software dedicated to imaging, and visualized as an image.
ITOコートスライドガラス(Glass Slides for MALDI Imaging : Part No. 237001)と、スライドガラスアダプタ ターゲット(MTP slide-adapter II : Part No. 235380)とを使用した。イオン源はMALDIを使用した。分離分析部はTOF-MSを使用した。データ処理部で使用するソフトウエアはBruker Daltonics社のflexImagingを使用した。 An ITO-coated slide glass (Glass Slides for MALDI Imaging: Part No. 237001) and a slide glass adapter target (MTP slide-adapter II: Part No. 235380) were used. MALDI was used as the ion source. The separation analysis unit used TOF-MS. The software used in the data processing section was Bruker Daltonics flexImaging.
試料は、ヒトアルツハイマー病ドナー組織切片を使用した。試料を70%エタノールで30秒洗浄し、次いで100%エタノールで30秒洗浄して脂質を除去し、次にカルノア液(無水エタノール:クロロホルム:(氷)酢酸=6:3:1)にて3分処理して組織固定し、次いで100%エタノールで30秒洗浄し、0.1%TFAで30秒洗浄し、真空乾燥させた後にITOコートスライドガラスに載置された。 The sample used was a human Alzheimer's disease donor tissue section. The sample was washed with 70% ethanol for 30 seconds, then washed with 100% ethanol for 30 seconds to remove the lipid, and then 3 times with Carnoy's solution (anhydrous ethanol: chloroform: (ice) acetic acid = 6: 3: 1). The tissue was fixed by partial treatment, then washed with 100% ethanol for 30 seconds, washed with 0.1% TFA for 30 seconds, vacuum-dried, and placed on an ITO-coated slide glass.
酸蒸気処理に使用する密閉容器としてふた付きのシャーレを用いた。シャーレに底上げのためにガラスバイアルを複数入れ、60℃に加熱した。次に、シャーレに100%ギ酸5mlを入れ、60℃に加熱した。温度一定後、ITOコートスライドガラスに載置された試料をバイアル上に設置した。この状態を図2に示す。次にシャーレのふたをしてインキュベータのカバーをし、60℃で5分間ギ酸気相で酸蒸気処理を行った。この状態を図3に示す。 A petri dish with a lid was used as an airtight container used for acid vapor treatment. A plurality of glass vials were placed in the petri dish to raise the bottom and heated to 60 ° C. Next, 5 ml of 100% formic acid was placed in a petri dish and heated to 60 ° C. After the temperature was fixed, the sample placed on the ITO-coated slide glass was placed on the vial. This state is shown in FIG. Next, the petri dish was covered and the incubator was covered, and acid vapor treatment was performed in a formic acid gas phase at 60 ° C. for 5 minutes. This state is shown in FIG.
次に、エアーブラシ2組を用い、酸蒸気処理された試料にマトリックスとハイドレーション液とを交互にスプレー塗布した。エアーブラシによる塗布ではスプレーから吐出される粒子径や飛散量を定量的に制御するように留意した。マトリックスは200mgのシナピン酸をアセトニトリルで溶解して作成した。ハイドレーション液は90%メタノール及び2%ギ酸にて作成した。 Next, two sets of air brushes were used to alternately apply a matrix and a hydration solution to the acid vapor-treated sample. In application with an air brush, care was taken to quantitatively control the particle size and the amount of scattering discharged from the spray. The matrix was prepared by dissolving 200 mg sinapinic acid in acetonitrile. Hydration solution was prepared with 90% methanol and 2% formic acid.
組織切片に対してMALDI-TOFMS測定を行った結果を図4に示した。左は、酸蒸気処理を行わず、右は酸蒸気処理を行ったヒト脳のアミロイドβ1-42のイメージング画像である。あきらかに酸蒸気処理によって同ペプチドの脳実質における分布の可視化が可能となった。 The results of MALDI-TOFMS measurement on tissue sections are shown in FIG. The left is an imaging image of human brain amyloid β1-42 that was not subjected to acid vapor treatment and the right was subjected to acid vapor treatment. Obviously, the acid vapor treatment made it possible to visualize the distribution of the peptide in the brain parenchyma.
生体組織切片のイメージング質量分析に利用できる。 It can be used for imaging mass spectrometry of biological tissue sections.
100:試料導入部
200:イオン源
300:分離分析部
400:データ処理部
900:イメージング質量分析装置
DESCRIPTION OF SYMBOLS 100: Sample introduction part 200: Ion source 300: Separation analysis part 400: Data processing part 900: Imaging mass spectrometer
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016231372A JP6877003B2 (en) | 2016-11-29 | 2016-11-29 | Pretreatment method for imaging mass spectrometry |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016231372A JP6877003B2 (en) | 2016-11-29 | 2016-11-29 | Pretreatment method for imaging mass spectrometry |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018087760A true JP2018087760A (en) | 2018-06-07 |
JP6877003B2 JP6877003B2 (en) | 2021-05-26 |
Family
ID=62494356
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016231372A Active JP6877003B2 (en) | 2016-11-29 | 2016-11-29 | Pretreatment method for imaging mass spectrometry |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6877003B2 (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060118711A1 (en) * | 2004-11-25 | 2006-06-08 | Canon Kabushiki Kaisha | In-plane distribution measurement method |
JP2007010658A (en) * | 2005-06-30 | 2007-01-18 | F Hoffmann La Roche Ag | Ionization modifier for mass spectrometry |
JP2009192548A (en) * | 2001-07-16 | 2009-08-27 | Caprotec Bioanalytics Gmbh | Captured compound, collection of the same, and analysis method of proteome and complex composition |
JP2012032298A (en) * | 2010-07-30 | 2012-02-16 | Nippi:Kk | Glycoprotein sample preparation method and analytic method |
JP2012233925A (en) * | 2012-09-05 | 2012-11-29 | Canon Inc | Mass spectroscope, ionizing agent for mass spectrometry, and mass spectrometric method |
WO2014163179A1 (en) * | 2013-04-04 | 2014-10-09 | 株式会社島津製作所 | Maldi sample preparation method and sample preparation device |
-
2016
- 2016-11-29 JP JP2016231372A patent/JP6877003B2/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009192548A (en) * | 2001-07-16 | 2009-08-27 | Caprotec Bioanalytics Gmbh | Captured compound, collection of the same, and analysis method of proteome and complex composition |
US20060118711A1 (en) * | 2004-11-25 | 2006-06-08 | Canon Kabushiki Kaisha | In-plane distribution measurement method |
JP2006153493A (en) * | 2004-11-25 | 2006-06-15 | Canon Inc | Information acquiring method |
JP2007010658A (en) * | 2005-06-30 | 2007-01-18 | F Hoffmann La Roche Ag | Ionization modifier for mass spectrometry |
JP2012032298A (en) * | 2010-07-30 | 2012-02-16 | Nippi:Kk | Glycoprotein sample preparation method and analytic method |
JP2012233925A (en) * | 2012-09-05 | 2012-11-29 | Canon Inc | Mass spectroscope, ionizing agent for mass spectrometry, and mass spectrometric method |
WO2014163179A1 (en) * | 2013-04-04 | 2014-10-09 | 株式会社島津製作所 | Maldi sample preparation method and sample preparation device |
Also Published As
Publication number | Publication date |
---|---|
JP6877003B2 (en) | 2021-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Škrášková et al. | Enhanced capabilities for imaging gangliosides in murine brain with matrix-assisted laser desorption/ionization and desorption electrospray ionization mass spectrometry coupled to ion mobility separation | |
Meriaux et al. | Liquid ionic matrixes for MALDI mass spectrometry imaging of lipids | |
Taban et al. | Imaging of peptides in the rat brain using MALDI-FTICR mass spectrometry | |
Yates III | Mass spectrometry and the age of the proteome | |
Sampson et al. | Intact and top-down characterization of biomolecules and direct analysis using infrared matrix-assisted laser desorption electrospray ionization coupled to FT-ICR mass spectrometry | |
US9202680B2 (en) | Mass spectometry using laserspray ionization | |
Bich et al. | Cluster TOF‐SIMS imaging as a tool for micrometric histology of lipids in tissue | |
Chen et al. | A high resolution atmospheric pressure matrix-assisted laser desorption/ionization-quadrupole-orbitrap MS platform enables in situ analysis of biomolecules by multi-mode ionization and acquisition | |
Trimpin et al. | New ionization processes and applications for use in mass spectrometry | |
Kondrat et al. | Native mass spectrometry: towards high-throughput structural proteomics | |
US20140027631A1 (en) | Systems and Methods Extending the Laserspray Ionization Mass Spectrometry Concept from Atmospheric Pressure to Vacuum | |
Harron et al. | High mass resolution tissue imaging at atmospheric pressure using laserspray ionization mass spectrometry | |
Schröter et al. | The combination of 2, 5-dihydroxybenzoic acid and 2, 5-dihydroxyacetophenone matrices for unequivocal assignment of phosphatidylethanolamine species in complex mixtures | |
Chen et al. | Matrix-assisted ionization vacuum for protein detection, fragmentation and PTM analysis on a high resolution linear ion trap-orbitrap platform | |
Pettit et al. | Infrared laser ablation sampling coupled with data independent high resolution UPLC-IM-MS/MS for tissue analysis | |
Susniak et al. | Recent developments in MALDI MSI application in plant tissues analysis | |
Nakanishi et al. | Topologies of amyloidogenic proteins in Congo red-positive sliced sections of formalin-fixed paraffin embedded tissues by MALDI-MS imaging coupled with on-tissue tryptic digestion | |
El-Baba et al. | Toward high spatial resolution sampling and characterization of biological tissue surfaces using mass spectrometry | |
WO2011073740A1 (en) | Matrices for mass spectrometry imaging | |
JP6877003B2 (en) | Pretreatment method for imaging mass spectrometry | |
JP2013105737A (en) | Microscopic laser mass spectrometer | |
EP2317323A1 (en) | MALDI Mass Spectrometry (MALDI-MS) for proteins of high molecular weight | |
Gulin et al. | Visualization of the spatial distribution of Pt+ ions in cisplatin-treated glioblastoma cells by time-of-flight secondary ion mass spectrometry | |
Tomalová et al. | On initial ion velocities in MALDI: A novel FT-ICR MS approach | |
Bruinen et al. | ToF-SIMS parallel imaging MS/MS of lipid species in thin tissue sections |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20170106 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170106 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191118 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20191118 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20191118 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200821 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200929 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201028 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210330 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210419 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6877003 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |